Although clinical development of c-Myc-Max inhibitors, including 10058-F4, is limited by their relatively low potencies [19], we needed to explore the effect of targeting the interaction between c-Myc and Max by 10058-F4 on ovarian cancer cells because little or no advancements have been made in ovarian cancer treatment over the last thirty years. Here, MAX is linked to ovarian carcinoma.